CASI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2026Q1

0.00

-100%

-0.400

-27.27%

0.00

-100%

-0.360

-47.83%

Estimates Revision

The market is revising No Change the revenue expectations for CASI Pharmaceuticals, Inc. (CASI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -44.44%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-44.44%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CASI is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

HC Wainwright & Co.

Sean Lee

Strong Buy

Maintains

$6 → $4

2025-04-09

Reason

HC Wainwright & Co.

Sean Lee

Price Target

$6 → $4

2025-04-09

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for CASI Pharmaceuticals Inc (CASI.O) is -0.58, compared to its 5-year average forward P/E of -3.45. For a more detailed relative valuation and DCF analysis to assess CASI Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.45

Current PE

-0.58

Overvalued PE

0.48

Undervalued PE

-7.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.43

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.65

Undervalued EV/EBITDA

-4.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.61

Current PS

0.00

Overvalued PS

5.55

Undervalued PS

-0.33

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CASI News & Events

Events Timeline

No data

News

8.5

2025-08-18Benzinga

Dayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading

2.0

2025-08-18NASDAQ.COM

Premarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers

9.5

2025-08-12NASDAQ.COM

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

People Also Watch

Frequently Asked Questions

What is CASI Pharmaceuticals Inc (CASI) stock price today?

The current price of CASI is 1.1 USD — it has increased 3.29 % in the last trading day.

What is CASI Pharmaceuticals Inc (CASI)'s business?

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

What is the price predicton of CASI Stock?

What is CASI Pharmaceuticals Inc (CASI)'s revenue for the last quarter?

CASI Pharmaceuticals Inc revenue for the last quarter amounts to 3.08M USD, decreased -60.54 % YoY.

What is CASI Pharmaceuticals Inc (CASI)'s earnings per share (EPS) for the last quarter?

CASI Pharmaceuticals Inc. EPS for the last quarter amounts to -0.68 USD, increased 23.64 % YoY.

What changes have occurred in the market's expectations for CASI Pharmaceuticals Inc (CASI)'s fundamentals?

How many employees does CASI Pharmaceuticals Inc (CASI). have?

CASI Pharmaceuticals Inc (CASI) has 233 emplpoyees as of January 10 2026.

What is CASI Pharmaceuticals Inc (CASI) market cap?

Today CASI has the market capitalization of 22.60M USD.